• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. MONDAY DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX

    MONDAY DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX

  2. Managing Expectations, Part II

    On Thursday, Human Genome Sciences HGSI announced full positive Phase IIb Albuferon trial results from a study done on genotype 1 hepatitis C patients. We are maintaining our fair value estimate as we had already assigned a success rate for Albuferon equivalent to a Phase III drug when interim data ...

  3. UPDATE: 10 stocks suffering the biggest cuts in earnings estimates

    UPDATE: 10 stocks suffering the biggest cuts in earnings estimates

  4. UPDATE: Amazon up on new payment service, King drops on outlook

    UPDATE: Amazon up on new payment service, King drops on outlook

  5. UPDATE: Amazon up on new payment service, King drops on outlook

    UPDATE: Amazon up on new payment service, King drops on outlook

  6. UPDATE: Kinder Morgan soars, Tesla rallies on upgrade

    UPDATE: Kinder Morgan soars, Tesla rallies on upgrade

  7. UPDATE: Kinder Morgan soars, Tesla rallies on upgrade

    UPDATE: Kinder Morgan soars, Tesla rallies on upgrade

  8. Charting the approach of S&P 2,000 -3-

    Charting the approach of S&P 2,000 -3-

  9. Charting the approach of S&P 2,000 -4-

    Charting the approach of S&P 2,000 -4-

  10. Charting the approach of S&P 2,000 -2-

    Charting the approach of S&P 2,000 -2-

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.